BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19837465)

  • 1. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
    Smith JL; Bu W; Burdick RC; Pathak VK
    Trends Pharmacol Sci; 2009 Dec; 30(12):638-46. PubMed ID: 19837465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
    Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
    mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
    Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
    J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
    J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
    Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
    J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
    Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
    J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
    Green LA; Liu Y; He JJ
    J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
    Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
    J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.